Wedbush began coverage on shares of Gossamer Bio (NASDAQ:GOSS – Get Rating) in a research note released on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $24.00 price objective on the stock. Wedbush also issued estimates for Gossamer Bio's Q3 2022 earnings at ($0.84) EPS, Q4 2022 earnings at ($0.84) EPS, FY2022 earnings at ($3.17) EPS, Q1 2023 earnings at ($0.84) EPS, Q2 2023 earnings at ($0.85) EPS, Q3 2023 earnings at ($0.86) EPS, Q4 2023 earnings at ($0.86) EPS, FY2023 earnings at ($3.41) EPS, FY2024 earnings at ($3.52) EPS, FY2025 earnings at ($3.64) EPS and FY2026 earnings at ($2.97) EPS.

Other analysts also recently issued reports about the company. Barclays boosted their price target on Gossamer Bio from $12.00 to $18.00 and gave the company an overweight rating in a research note on Wednesday, August 17th. HC Wainwright reaffirmed a buy rating and issued a $20.00 target price on shares of Gossamer Bio in a report on Thursday, July 14th. Finally, Raymond James upped their target price on Gossamer Bio from $10.00 to $14.00 and gave the stock an outperform rating in a report on Thursday, July 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Gossamer Bio has a consensus rating of Moderate Buy and an average target price of $19.10.

Gossamer Bio Price Performance

Shares of GOSS opened at $12.56 on Monday. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 7.44. Gossamer Bio has a 1 year low of $5.64 and a 1 year high of $15.19. The stock has a market cap of $1.18 billion, a P/E ratio of -4.13 and a beta of 0.92. The stock's 50-day moving average price is $13.18 and its two-hundred day moving average price is $9.83.

Insider Activity at Gossamer Bio

In other Gossamer Bio news, insider Laura Carter sold 8,808 shares of Gossamer Bio stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $8.25, for a total transaction of $72,666.00. Following the sale, the insider now directly owns 80,234 shares of the company's stock, valued at approximately $661,930.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Gossamer Bio news, CEO Faheem Hasnain purchased 138,696 shares of the stock in a transaction that occurred on Friday, July 15th. The stock was purchased at an average price of $7.21 per share, with a total value of $999,998.16. Following the acquisition, the chief executive officer now owns 3,617,325 shares in the company, valued at $26,080,913.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Laura Carter sold 8,808 shares of the stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $8.25, for a total transaction of $72,666.00. Following the completion of the sale, the insider now directly owns 80,234 shares in the company, valued at $661,930.50. The disclosure for this sale can be found here. Insiders have acquired a total of 159,499 shares of company stock worth $1,149,988 in the last 90 days. Company insiders own 8.30% of the company's stock.

Institutional Investors Weigh In On Gossamer Bio

Several institutional investors have recently bought and sold shares of GOSS. Millennium Management LLC raised its holdings in shares of Gossamer Bio by 281.0% during the second quarter. Millennium Management LLC now owns 1,480,705 shares of the company's stock worth $12,394,000 after purchasing an additional 1,092,018 shares during the last quarter. Woodline Partners LP acquired a new position in Gossamer Bio during the fourth quarter worth about $11,059,000. Point72 Asset Management L.P. acquired a new position in Gossamer Bio during the second quarter worth about $8,064,000. Kynam Capital Management LP boosted its holdings in Gossamer Bio by 80.2% in the 1st quarter. Kynam Capital Management LP now owns 1,832,704 shares of the company's stock valued at $15,908,000 after purchasing an additional 815,847 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Gossamer Bio by 17.1% in the 2nd quarter. State Street Corp now owns 3,875,194 shares of the company's stock worth $32,435,000 after acquiring an additional 567,264 shares during the last quarter. 67.57% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

(Get Rating)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Read More

• Get a free copy of the StockNews.com research report on Gossamer Bio (GOSS)
• The Worst May be Over for Target, But is the Stock Safe to Buy?
• Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
• Two Fun Stocks The Insiders Are Buying
• Novavax Remains a Risk-On Stock in a Risk-Off Market
• General Mills: Superior Returns With Less Volatility

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.